Peter van der Meer

Cardiologist

Professor Peter van der Meer received both his MD and PhD cum laude from the University of Groningen in the Netherlands. He is trained as a cardiologist with a focus on heart failure and cardiac devices. He did a postdoctoral fellowship at Harvard Medical School with prof. Ken Chien to further train his skills in cardiac stem cell biology.

The group of Prof. Van der Meer consists of PhD students, technicians and post-docs with various backgrounds (biologists, medical doctors, and biomedical-engineers) working on translational research topics to bridge the gap between bench and bedside. His group focuses on understanding the susceptibility to develop heart failure and exploring novel treatment targets and therapies. He is a member of several steering committees of large morbidity and mortality trials investigating the impact of new and old drugs in patients with heart failure, including digoxin and iron.

We are always happy to discuss positions and vacancies with highly motivated and ambitious (bio)medical students with a strong affiliation with topics related to heart failure, in vitro disease modeling, clinical studies, statistics, and/or epidemiology. We often host visiting scientist from abroad.

Contact details

Current activities

Prof. Van der Meer is a member of the ESC council of cardio-oncology, member of the working group on translational cardiology and peripartum cardiomyopathy of the ESC and associate editor of the European Journal of Heart Failure. He is currently medical director of the coronary care unit of the University Medical Center Groningen.

“A better understanding of why patients develop heart failure will eventually lead to a targeted approach and precision medicine.”

My projects

DECISION

Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands: DECISION

STOP-HF

Stem cell models to unravel the susceptibility and resilience to develop heart failure

PLN cardiomyopathy

Investigating and treating phospholamban cardiomyopathy

Selenium and Heart Failure

Translational research focusing on synergy between lifestyle interventions and treating HF.

KETONE-HF

Harnessing the power of ketones

BIOSTAT-CHF

Facilitate personalized therapies in patients with heart failure

SECRETE-HF

Secreted factors in cardiac remodeling provoke tumorigenesis and end organ damage in heart failure

My publications

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.

Heart failure with preserved ejection fraction and AF are very common diseases that also often occur in combination, further aggravating each other. Senile amyloidosis, either due to TTR (ATTRwt) or ANP (IAA) appears to play an important role in both diseases and in their interaction. In terms of diagnostics, bone scintigraphy has become available and affords an easy and reliable way to establish the presence of cardiac ATTRwt. Moreover, pharmacological options are now available or under development to treat ATTRwt and possibly also IAA, thereby potentially stopping, or even reversing, the downhill course of some patients with HFpEF and AF.

view on Oxford Academic

Sex-specific associations of obesity and N-Terminal Pro-B-Type Natriuretic Peptide levels in the general population

Navin Suthahar, Wouter C Meijers, Jennifer E Ho, Ron T Gansevoort, Adriaan A Voors, Peter van der Meer, Stephan J L Bakker, Stephane Heymans, Vanessa van Empel, Blanche Schroen, Pim van der Harst, Dirk J van Veldhuisen, and Rudolf A de Boer. Eur J Heart Fail. 2018.

view on PubMed

Pathophysiology, Diagnosis and Management of Peripartum Cardiomyopathy: A Position Statement From the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Johann Bauersachs, Tobias König Peter van der Meer Mark C. Petrie Denise Hilfiker‐Kleiner Amam Mbakwem Righab Hamdan Alice M. Jackson Paul Forsyth Rudolf A. de Boer Christian Mueller Alexander R. Lyon Lars H. Lund Massimo F. Piepoli Stephane Heymans Ovidiu Chioncel Stefan D. Anker Piotr Ponikowski Petar M. Seferovic Mark R. Johnson Alexandre Mebazaa Karen Sliwa. Eur J Heart Fail. 2019.

view on publisher site

Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH.

Van der Pol A, Gil A, Silljé HHW, Tromp J, Ovchinnikova ES, Vreeswijk-Baudoin I, Hoes M, Domian IJ, van de Sluis B, van Deursen JM, Voors AA, van Veldhuisen DJ, van Gilst WH, Berezikov E, van der Harst P, de Boer RA, Bischoff R, van der Meer P. Science Transl Med. 2017.

view on publisher site

Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.

Van der Wal HH, Grote Beverborg N, Dickstein K, Anker SD, Lang CC, Ng LL, van Veldhuisen DJ, Voors AA, Van der Meer P. Eur Heart J. 2019.

view on publisher site